FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 353:2667-2672 December 22, 2005 Number 25 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Supplementary Material Perspective by Moscona, A. Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

SUMMARY

Influenza A (H5N1) virus with an amino acid substitution in neuraminidase conferring high-level resistance to oseltamivir was isolated from two of eight Vietnamese patients during oseltamivir treatment. Both patients died of influenza A (H5N1) virus infection, despite early initiation of treatment in one patient. Surviving patients had rapid declines in the viral load to undetectable levels during treatment. These observations suggest that resistance can emerge during the currently recommended regimen of oseltamivir therapy and may be associated with clinical deterioration and that the strategy for the treatment of influenza A (H5N1) virus infection should include additional antiviral agents.

Source Information

From the Oxford University Clinical Research Unit, Hospital for Tropical Diseases (M.D.J., T.T.T., D.Q.H., J.F.), Pediatric Hospital Number One (T.H.K., B.V.C., P.T.Q.), and the Hospital for Tropical Diseases (V.M.H., N.V.C., T.T.H.)— all in Ho Chi Minh City, Vietnam; and the Department of Microbiology, University of Hong Kong, Queen Mary Hospital, Hong Kong Special Administrative Region, China (G.J.D.S., Y.G., J.S.M.P.).

Address reprint requests to Dr. de Jong at the Oxford University Clinical Research Unit, Hospital for Tropical Diseases, 190 Ben Ham Tu, District 5, Ho Chi Minh City, Vietnam, or at mddejong{at}hcm.vnn.vn.

Full Text of this Article

Related Letters:

Oseltamivir Resistance in Influenza A (H5N1) Infection
Gupta R. K., Nguyen-Van-Tam J. S., de Jong M. D., Hien T. T., Farrar J.
Extract | Full Text | PDF  
N Engl J Med 2006; 354:1423-1424, Mar 30, 2006. Correspondence

This article has been cited by other articles:

• Baz, M., Abed, Y., Papenburg, J., Bouhy, X., Hamelin, M.-E., Boivin, G. (2009). Emergence of Oseltamivir-Resistant Pandemic H1N1 Virus during Prophylaxis. NEJM 0: NEJMc0910060v1-1 [Full Text]  
• Shih, S.-R., Horng, J.-T., Poon, L. L. M., Chen, T.-C., Yeh, J.-Y., Hsieh, H.-P., Tseng, S.-N., Chiang, C., Li, W.-L., Chao, Y.-S., Hsu, J. T.-A. (2009). BPR2-D2 targeting viral ribonucleoprotein complex-associated function inhibits oseltamivir-resistant influenza viruses. J Antimicrob Chemother 0: dkp393v2-dkp393 [Abstract] [Full Text]  
• Hurt, A. C., Holien, J. K., Parker, M., Kelso, A., Barr, I. G. (2009). Zanamivir-Resistant Influenza Viruses with a Novel Neuraminidase Mutation. J. Virol. 83: 10366-10373 [Abstract] [Full Text]  
• Khazeni, N., Hutton, D. W., Garber, A. M., Owens, D. K. (2009). Effectiveness and Cost-Effectiveness of Expanded Antiviral Prophylaxis and Adjuvanted Vaccination Strategies for an Influenza A (H5N1) Pandemic. ANN INTERN MED 0: 0000605-200912150-00156v1-E-156 [Abstract] [Full Text]  
• Nguyen, J. T., Hoopes, J. D., Smee, D. F., Prichard, M. N., Driebe, E. M., Engelthaler, D. M., Le, M. H., Keim, P. S., Spence, R. P., Went, G. T. (2009). Triple Combination of Oseltamivir, Amantadine, and Ribavirin Displays Synergistic Activity against Multiple Influenza Virus Strains In Vitro. Antimicrob. Agents Chemother. 53: 4115-4126 [Abstract] [Full Text]  
• Hurt, A. C., Holien, J. K., Barr, I. G. (2009). In Vitro Generation of Neuraminidase Inhibitor Resistance in A(H5N1) Influenza Viruses. Antimicrob. Agents Chemother. 53: 4433-4440 [Abstract] [Full Text]  
• Milne, G., Kelso, J., Kelly, H. (2009). Strategies for mitigating an influenza pandemic with pre-pandemic H5N1 vaccines. J R Soc Interface 0: rsif.2009.0312v1-rsif20090312 [Abstract] [Full Text]  
• Govorkova, E. A., Ilyushina, N. A., McClaren, J. L., Naipospos, T. S. P., Douangngeun, B., Webster, R. G. (2009). Susceptibility of Highly Pathogenic H5N1 Influenza Viruses to the Neuraminidase Inhibitor Oseltamivir Differs In Vitro and in a Mouse Model. Antimicrob. Agents Chemother. 53: 3088-3096 [Abstract] [Full Text]  
• Fraser, C., Donnelly, C. A., Cauchemez, S., Hanage, W. P., Van Kerkhove, M. D., Hollingsworth, T. D., Griffin, J., Baggaley, R. F., Jenkins, H. E., Lyons, E. J., Jombart, T., Hinsley, W. R., Grassly, N. C., Balloux, F., Ghani, A. C., Ferguson, N. M., Rambaut, A., Pybus, O. G., Lopez-Gatell, H., Alpuche-Aranda, C. M., Chapela, I. B., Zavala, E. P., Guevara, D. Ma. E., Checchi, F., Garcia, E., Hugonnet, S., Roth, C., The WHO Rapid Pandemic Assessment Collaboration, (2009). Pandemic Potential of a Strain of Influenza A (H1N1): Early Findings. Science 324: 1557-1561 [Abstract] [Full Text]  
• Fleming, D. M., Elliot, A. J., Meijer, A., Paget, W. J. (2009). Influenza virus resistance to oseltamivir: what are the implications?. Eur J Public Health 19: 238-239 [Full Text]  
• Smee, D. F., Hurst, B. L., Wong, M.-H., Bailey, K. W., Morrey, J. D. (2009). Effects of Double Combinations of Amantadine, Oseltamivir, and Ribavirin on Influenza A (H5N1) Virus Infections in Cell Culture and in Mice. Antimicrob. Agents Chemother. 53: 2120-2128 [Abstract] [Full Text]  
• Van Hoeven, N., Belser, J. A., Szretter, K. J., Zeng, H., Staeheli, P., Swayne, D. E., Katz, J. M., Tumpey, T. M. (2009). Pathogenesis of 1918 Pandemic and H5N1 Influenza Virus Infections in a Guinea Pig Model: Antiviral Potential of Exogenous Alpha Interferon To Reduce Virus Shedding. J. Virol. 83: 2851-2861 [Abstract] [Full Text]  
• Wattanagoon, Y., Stepniewska, K., Lindegardh, N., Pukrittayakamee, S., Silachamroon, U., Piyaphanee, W., Singtoroj, T., Hanpithakpong, W., Davies, G., Tarning, J., Pongtavornpinyo, W., Fukuda, C., Singhasivanon, P., Day, N. P. J., White, N. J. (2009). Pharmacokinetics of High-Dose Oseltamivir in Healthy Volunteers. Antimicrob. Agents Chemother. 53: 945-952 [Abstract] [Full Text]  
• Deyde, V. M., Nguyen, T., Bright, R. A., Balish, A., Shu, B., Lindstrom, S., Klimov, A. I., Gubareva, L. V. (2009). Detection of Molecular Markers of Antiviral Resistance in Influenza A (H5N1) Viruses Using a Pyrosequencing Method. Antimicrob. Agents Chemother. 53: 1039-1047 [Abstract] [Full Text]  
• Gabbard, J., Velappan, N., Di Niro, R., Schmidt, J., Jones, C.A., Tompkins, S.M., Bradbury, A.R.M. (2009). A humanized anti-M2 scFv shows protective in vitro activity against influenza. Protein Eng Des Sel 22: 189-198 [Abstract] [Full Text]  
• Baz, M., Abed, Y., Nehme, B., Boivin, G. (2009). Activity of the Oral Neuraminidase Inhibitor A-322278 against the Oseltamivir-Resistant H274Y (A/H1N1) Influenza Virus Mutant in Mice. Antimicrob. Agents Chemother. 53: 791-793 [Abstract] [Full Text]  
• Seet, R.C.-S., Lim, E.C.H., Oh, V.M.S., Ong, B.K.C., Goh, K.T., Fisher, D.A., Ho, K.Y., Yeoh, K.G. (2009). Readiness exercise to combat avian influenza. QJM 102: 133-137 [Abstract] [Full Text]  
• Maxmen, A. (2009). Jeremy Farrar: When disaster strikes. JEM 206: 4-5 [Full Text]  
• Ilyushina, N. A., Hay, A., Yilmaz, N., Boon, A. C. M., Webster, R. G., Govorkova, E. A. (2008). Oseltamivir-Ribavirin Combination Therapy for Highly Pathogenic H5N1 Influenza Virus Infection in Mice. Antimicrob. Agents Chemother. 52: 3889-3897 [Abstract] [Full Text]  
• Simmons, C., Farrar, J. (2008). Insights into Inflammation and Influenza. NEJM 359: 1621-1623 [Full Text]  
• Sheu, T. G., Deyde, V. M., Okomo-Adhiambo, M., Garten, R. J., Xu, X., Bright, R. A., Butler, E. N., Wallis, T. R., Klimov, A. I., Gubareva, L. V. (2008). Surveillance for Neuraminidase Inhibitor Resistance among Human Influenza A and B Viruses Circulating Worldwide from 2004 to 2008. Antimicrob. Agents Chemother. 52: 3284-3292 [Abstract] [Full Text]  
• Moghadas, S. M (2008). Management of drug resistance in the population: influenza as a case study. Proc R Soc B 275: 1163-1169 [Abstract] [Full Text]  
• Thomas, Y., Vogel, G., Wunderli, W., Suter, P., Witschi, M., Koch, D., Tapparel, C., Kaiser, L. (2008). Survival of Influenza Virus on Banknotes. Appl. Environ. Microbiol. 74: 3002-3007 [Abstract] [Full Text]  
• Arinaminpathy, N, McLean, A.R (2008). Antiviral treatment for the control of pandemic influenza: some logistical constraints. J R Soc Interface 5: 545-553 [Abstract] [Full Text]  
• Sandrock, C., Stollenwerk, N. (2008). Acute Febrile Respiratory Illness in the ICU: Reducing Disease Transmission. Chest 133: 1221-1231 [Abstract] [Full Text]  
• Christian, M. D., Devereaux, A. V., Dichter, J. R., Geiling, J. A., Rubinson, L. (2008). Definitive Care for the Critically Ill During a Disaster: Current Capabilities and Limitations: From a Task Force for Mass Critical Care Summit Meeting, January 26-27, 2007, Chicago, IL. Chest 133: 8S-17S [Abstract] [Full Text]  
• Korteweg, C., Gu, J. (2008). Pathology, Molecular Biology, and Pathogenesis of Avian Influenza A (H5N1) Infection in Humans. Am. J. Pathol. 172: 1155-1170 [Abstract] [Full Text]  
• Gabriel, G., Nordmann, A., Stein, D. A., Iversen, P. L., Klenk, H.-D. (2008). Morpholino oligomers targeting the PB1 and NP genes enhance the survival of mice infected with highly pathogenic influenza A H7N7 virus. J. Gen. Virol. 89: 939-948 [Abstract] [Full Text]  
• Watanabe, T., Watanabe, S., Kim, J. H., Hatta, M., Kawaoka, Y. (2008). Novel Approach to the Development of Effective H5N1 Influenza A Virus Vaccines: Use of M2 Cytoplasmic Tail Mutants. J. Virol. 82: 2486-2492 [Abstract] [Full Text]  
• Ruat, C., Caillet, C., Bidaut, A., Simon, J., Osterhaus, A. D. M. E. (2008). Vaccination of Macaques with Adjuvanted Formalin-Inactivated Influenza A Virus (H5N1) Vaccines: Protection against H5N1 Challenge without Disease Enhancement. J. Virol. 82: 2565-2569 [Abstract] [Full Text]  
• Writing Committee of the Second World Health Organ, (2008). Update on Avian Influenza A (H5N1) Virus Infection in Humans. NEJM 358: 261-273 [Full Text]  
• Yen, H.-L., Ilyushina, N. A., Salomon, R., Hoffmann, E., Webster, R. G., Govorkova, E. A. (2007). Neuraminidase Inhibitor-Resistant Recombinant A/Vietnam/1203/04 (H5N1) Influenza Viruses Retain Their Replication Efficiency and Pathogenicity In Vitro and In Vivo. J. Virol. 81: 12418-12426 [Abstract] [Full Text]  
• Debarre, F., Bonhoeffer, S., Regoes, R. R (2007). The effect of population structure on the emergence of drug resistance during influenza pandemics. J R Soc Interface 4: 893-906 [Abstract] [Full Text]  
• Zhou, B., Zhong, N., Guan, Y. (2007). Treatment with Convalescent Plasma for Influenza A (H5N1) Infection. NEJM 357: 1450-1451 [Full Text]  
• Ducatez, M. F., Olinger, C. M., Owoade, A. A., Tarnagda, Z., Tahita, M. C., Sow, A., De Landtsheer, S., Ammerlaan, W., Ouedraogo, J. B., Osterhaus, A. D. M. E., Fouchier, R. A. M., Muller, C. P. (2007). Molecular and antigenic evolution and geographical spread of H5N1 highly pathogenic avian influenza viruses in western Africa. J. Gen. Virol. 88: 2297-2306 [Abstract] [Full Text]  
• Alexander, M. E, Bowman, C. S, Feng, Z., Gardam, M., Moghadas, S. M, Rost, G., Wu, J., Yan, P. (2007). Emergence of drug resistance: implications for antiviral control of pandemic influenza. Proc R Soc B 274: 1675-1684 [Abstract] [Full Text]  
• Yin, C., Khan, J. A., Swapna, G. V. T., Ertekin, A., Krug, R. M., Tong, L., Montelione, G. T. (2007). Conserved Surface Features Form the Double-stranded RNA Binding Site of Non-structural Protein 1 (NS1) from Influenza A and B Viruses. J. Biol. Chem. 282: 20584-20592 [Abstract] [Full Text]  
• Yen, H.-L., Lipatov, A. S., Ilyushina, N. A., Govorkova, E. A., Franks, J., Yilmaz, N., Douglas, A., Hay, A., Krauss, S., Rehg, J. E., Hoffmann, E., Webster, R. G. (2007). Inefficient Transmission of H5N1 Influenza Viruses in a Ferret Contact Model. J. Virol. 81: 6890-6898 [Abstract] [Full Text]  
• Lindegardh, N., Davies, G. R., Hien, T. T., Farrar, J., Singhasivanon, P., Day, N. P. J., White, N. J. (2007). Importance of Collection Tube during Clinical Studies of Oseltamivir. Antimicrob. Agents Chemother. 51: 1835-1836 [Abstract] [Full Text]  
• Hatakeyama, S., Sugaya, N., Ito, M., Yamazaki, M., Ichikawa, M., Kimura, K., Kiso, M., Shimizu, H., Kawakami, C., Koike, K., Mitamura, K., Kawaoka, Y. (2007). Emergence of Influenza B Viruses With Reduced Sensitivity to Neuraminidase Inhibitors. JAMA 297: 1435-1442 [Abstract] [Full Text]  
• Peiris, J. S. M., de Jong, M. D., Guan, Y. (2007). Avian Influenza Virus (H5N1): a Threat to Human Health. Clin. Microbiol. Rev. 20: 243-267 [Abstract] [Full Text]  
• Govorkova, E. A., Ilyushina, N. A., Boltz, D. A., Douglas, A., Yilmaz, N., Webster, R. G. (2007). Efficacy of Oseltamivir Therapy in Ferrets Inoculated with Different Clades of H5N1 Influenza Virus. Antimicrob. Agents Chemother. 51: 1414-1424 [Abstract] [Full Text]  
• Tsiodras, S., Mooney, J. D, Hatzakis, A. (2007). Role of combination antiviral therapy in pandemic influenza and stockpiling implications. BMJ 334: 293-294 [Full Text]  
• Thomas, J. K., Noppenberger, J. (2007). Avian influenza: A review. Am J Health Syst Pharm 64: 149-165 [Abstract] [Full Text]  
• Jones, J. C., Turpin, E. A., Bultmann, H., Brandt, C. R., Schultz-Cherry, S. (2006). Inhibition of Influenza Virus Infection by a Novel Antiviral Peptide That Targets Viral Attachment to Cells. J. Virol. 80: 11960-11967 [Abstract] [Full Text]  
• Karie, S., Launay-Vacher, V., Janus, N., Izzedine, H., Deray, G. (2006). Pharmacokinetics and dosage adjustment of oseltamivir and zanamivir in patients with renal failure. Nephrol Dial Transplant 21: 3606-3608 [Full Text]  
• Kandun, I. N., Wibisono, H., Sedyaningsih, E. R., Yusharmen, , Hadisoedarsuno, W., Purba, W., Santoso, H., Septiawati, C., Tresnaningsih, E., Heriyanto, B., Yuwono, D., Harun, S., Soeroso, S., Giriputra, S., Blair, P. J., Jeremijenko, A., Kosasih, H., Putnam, S. D., Samaan, G., Silitonga, M., Chan, K.H., Poon, L. L.M., Lim, W., Klimov, A., Lindstrom, S., Guan, Y., Donis, R., Katz, J., Cox, N., Peiris, M., Uyeki, T. M. (2006). Three Indonesian Clusters of H5N1 Virus Infection in 2005.. NEJM 355: 2186-2194 [Abstract] [Full Text]  
• Democratis, J., Pareek, M., Stephenson, I. (2006). Use of neuraminidase inhibitors to combat pandemic influenza. J Antimicrob Chemother 58: 911-915 [Abstract] [Full Text]  
• Rameix-Welti, M. A., Agou, F., Buchy, P., Mardy, S., Aubin, J. T., Veron, M., van der Werf, S., Naffakh, N. (2006). Natural Variation Can Significantly Alter the Sensitivity of Influenza A (H5N1) Viruses to Oseltamivir. Antimicrob. Agents Chemother. 50: 3809-3815 [Abstract] [Full Text]  
• Lindegardh, N., Davies, G. R., Hien, T. T., Farrar, J., Singhasivanon, P., Day, N. P. J., White, N. J. (2006). Rapid degradation of oseltamivir phosphate in clinical samples by plasma esterases.. Antimicrob. Agents Chemother. 50: 3197-3199 [Abstract] [Full Text]  
• Bartlett, J. G. (2006). Planning for Avian Influenza. ANN INTERN MED 145: 141-144 [Abstract] [Full Text]  
• Monto, A. S., McKimm-Breschkin, J. L., Macken, C., Hampson, A. W., Hay, A., Klimov, A., Tashiro, M., Webster, R. G., Aymard, M., Hayden, F. G., Zambon, M. (2006). Detection of Influenza Viruses Resistant to Neuraminidase Inhibitors in Global Surveillance during the First 3 Years of Their Use.. Antimicrob. Agents Chemother. 50: 2395-2402 [Abstract] [Full Text]  
• Stephenson, I., Democratis, J. (2006). Influenza: current threat from avian influenza. Br Med Bull 75-76: 63-80 [Abstract] [Full Text]  
• Granados, A., Goodman, C., Eklund, L. (2006). Pandemic influenza: using evidence on vaccines and antivirals for clinical decisions and policy making.. Eur Respir J 27: 661-663 [Full Text]  
• Treanor, J. J., Campbell, J. D., Zangwill, K. M., Rowe, T., Wolff, M. (2006). Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine.. NEJM 354: 1343-1351 [Abstract] [Full Text]  
• Poland, G. A. (2006). Vaccines against avian influenza--a race against time.. NEJM 354: 1411-1413 [Full Text]  
• Gupta, R. K., Nguyen-Van-Tam, J. S., de Jong, M. D., Hien, T. T., Farrar, J. (2006). Oseltamivir resistance in influenza A (H5N1) infection.. NEJM 354: 1423-1424 [Full Text]  
• (2006). Two More Cases of Oseltamivir-Resistant Avian Influenza. JWatch Pediatrics 2006: 7-7 [Full Text]  
• Hayden, F. G. (2006). Antiviral resistance in influenza viruses--implications for management and pandemic response.. NEJM 354: 785-788 [Full Text]  
• Weinstock, D. M., Zuccotti, G. (2006). Adamantane Resistance in Influenza A. JAMA 295: 934-936 [Full Text]  
• Bonten, M. J M, Prins, J. M (2006). Antibiotics in pandemic flu. BMJ 332: 248-249 [Full Text]  
• (2006). Oseltamivir-Resistant Influenza A (H5N1) Infections in Humans. JWatch Infect. Diseases 2006: 3-3 [Full Text]  
• (2006). Two More Cases of Oseltamivir-Resistant Avian Influenza. JWatch General 2006: 2-2 [Full Text]  
• Parry, J. (2006). Uncertainty still surrounds oseltamivir after 13 year old dies. BMJ 332: 5-5 [Full Text]  
• Mudur, G. (2006). Indian firm to produce oseltamivir for developing countries. BMJ 332: 5-5 [Full Text]